The determination of the mechanism of MS-AEs would enable a focused approach to amelioration of symptoms, thus facilitating compliance and improving the benefits of AIs for women with early breast cancer.The genotyping result identified two SNPs rs2234693 and rs9340799 in ESR1 that were related to MS-AEs in patients receiving AIs adjuvant therapy. Here, ESR1 is linked to breast carcinoma.